HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Yoshihiro Shirai Selected Research

nafamostat

1/2022Phase II trial of nafamostat mesilate/gemcitabin/S-1 for unresectable pancreatic cancer.
1/2021Nafamostat mesilate, a nuclear factor kappa B inhibitor, enhances the antitumor action of radiotherapy on gallbladder cancer cells.
12/2019Prevention of early liver metastasis after pancreatectomy by perioperative administration of a nuclear factor-κB inhibitor in mice.
1/2019Correction: Hiroshi Sugano et al. Nafamostat Mesilate Enhances the Radiosensitivity and Reduces the Radiation-Induced Invasive Ability of Colorectal Cancer Cells. Cancers 2018, 10, 386.
10/2018Nafamostat Mesilate Enhances the Radiosensitivity and Reduces the Radiation-Induced Invasive Ability of Colorectal Cancer Cells.
1/2018Glycogen synthase kinase-3β activity plays a key role in the antitumor effect of nafamostat mesilate in pancreatic cancer cells.
11/2016New treatment strategy with nuclear factor-κB inhibitor for pancreatic cancer.
1/2016Dual inhibition of nuclear factor kappa-B and Mdm2 enhance the antitumor effect of radiation therapy for pancreatic cancer.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown:


Yoshihiro Shirai Research Topics

Disease

34Neoplasms (Cancer)
10/2022 - 09/2014
20Pancreatic Neoplasms (Pancreatic Cancer)
12/2022 - 01/2016
8Neoplasm Metastasis (Metastasis)
07/2022 - 09/2014
5Liver Cirrhosis (Hepatic Cirrhosis)
07/2022 - 01/2018
5Hepatocellular Carcinoma (Hepatoma)
04/2022 - 01/2018
5Adenocarcinoma
01/2021 - 09/2015
4Pancreatic Fistula (Pancreatic Fistulas)
03/2021 - 01/2015
3Carcinoma (Carcinomatosis)
04/2022 - 01/2016
3Thrombosis (Thrombus)
03/2022 - 11/2020
2Mitochondrial Diseases (Mitochondrial Disease)
10/2022 - 11/2021
2Fibrosis (Cirrhosis)
07/2022 - 01/2021
2Biliary Tract Neoplasms (Biliary Tract Cancer)
07/2022 - 04/2022
2Bile Duct Neoplasms (Bile Duct Cancer)
03/2022 - 09/2015
2Metabolic Bone Diseases (Osteopenia)
03/2022 - 10/2021
2Pancreatitis
01/2022 - 06/2015
2Cholangiocarcinoma
12/2021 - 01/2018
2Ascites
12/2021 - 01/2018
2Margins of Excision
11/2021 - 10/2021
2Colorectal Neoplasms (Colorectal Cancer)
01/2019 - 10/2018
2Inflammation (Inflammations)
01/2019 - 09/2016
1Lymphatic Metastasis
07/2022
1Residual Neoplasm
07/2022
1Neutropenia
04/2022
1Idiopathic Noncirrhotic Portal Hypertension
04/2022
1Diabetes Mellitus
04/2022
1Esophageal and Gastric Varices (Esophageal Varices)
04/2022
1Focal Nodular Hyperplasia
04/2022
1Sarcopenia
03/2022
1Carcinoma in Situ
01/2022
1Portal Hypertension
01/2022
1Hepatitis C
01/2022
1Hepatitis B
12/2021
1Hypertrophy
12/2021
1Virus Diseases (Viral Diseases)
12/2021
1Insulinoma
06/2021
1Neuroendocrine Tumors (Neuroendocrine Tumor)
06/2021
1Primitive Neuroectodermal Tumors (PNET)
06/2021
1Venous Thromboembolism
05/2021

Drug/Important Bio-Agent (IBA)

8nafamostatIBA
01/2022 - 01/2016
7GemcitabineFDA Link
01/2022 - 11/2016
5Indicators and Reagents (Reagents)IBA
10/2021 - 09/2015
4Proteins (Proteins, Gene)FDA Link
04/2022 - 12/2021
4NF-kappa B (NF-kB)IBA
01/2021 - 01/2016
4AlbuminsIBA
01/2018 - 09/2016
3Indocyanine Green (Cardio-Green)FDA LinkGeneric
12/2021 - 01/2018
3C-Reactive ProteinIBA
10/2021 - 09/2016
3130-nm albumin-bound paclitaxelIBA
10/2020 - 11/2016
3Serine Proteinase Inhibitors (Serine Protease Inhibitors)IBA
12/2019 - 01/2016
2EnzymesIBA
10/2022 - 04/2022
2AcidsIBA
10/2022 - 06/2021
2Cisplatin (Platino)FDA LinkGeneric
12/2021 - 10/2018
2Transferrin (beta 2 Transferrin)IBA
12/2021 - 08/2021
2Small Interfering RNA (siRNA)IBA
11/2021 - 06/2021
2ThrombomodulinIBA
07/2021 - 01/2017
2AmylasesFDA Link
01/2021 - 11/2016
2Matrix Metalloproteinases (MMPs)IBA
12/2019 - 10/2018
2pomalidomideIBA
03/2018 - 03/2018
2Pharmaceutical PreparationsIBA
03/2018 - 07/2016
1SphingolipidsIBA
10/2022
1GlucosidasesIBA
10/2022
1Omega-3 Fatty Acids (Omega 3 Fatty Acids)IBA
04/2022
1Fatty Acids (Saturated Fatty Acids)IBA
04/2022
1Pancrelipase (Creon)FDA Link
04/2022
1Eicosapentaenoic AcidIBA
04/2022
1XELOXIBA
04/2022
1acarboxyprothrombin (PIVKA)IBA
04/2022
1Vitamin KFDA Link
04/2022
1folfirinoxIBA
03/2022
1Antiviral Agents (Antivirals)IBA
01/2022
1Retinol-Binding Proteins (Retinoid Binding Proteins)IBA
12/2021
1Prealbumin (Transthyretin)IBA
12/2021
1CeramidesIBA
11/2021
1Fetal Proteins (Fetoprotein)IBA
11/2021
1Superoxide DismutaseIBA
11/2021
1Reactive Oxygen Species (Oxygen Radicals)IBA
11/2021
1Acid CeramidaseIBA
11/2021
1Biomarkers (Surrogate Marker)IBA
10/2021
1ParaffinIBA
07/2021
1Transcription Factors (Transcription Factor)IBA
06/2021
1alpha-Glucosidases (Acid Maltase)IBA
06/2021
1fibrin fragment D (D-dimer)IBA
05/2021
1Triglycerides (Triacylglycerol)IBA
03/2021
1CholesterolIBA
02/2021

Therapy/Procedure

10Hepatectomy
07/2022 - 11/2020
9Pancreaticoduodenectomy
03/2022 - 01/2015
8Drug Therapy (Chemotherapy)
04/2022 - 01/2016
7Pancreatectomy
12/2022 - 06/2015
7Therapeutics
04/2022 - 01/2014
4Lymph Node Excision (Lymph Node Dissection)
12/2022 - 05/2021
3Combination Drug Therapy (Combination Chemotherapy)
01/2022 - 03/2018
3Radiotherapy
01/2021 - 01/2016
2Operative Time
07/2022 - 03/2021
2Adjuvant Chemotherapy
07/2022 - 04/2022
2Ligation
04/2022 - 12/2021
1Nutrition Therapy (Medical Nutrition Therapy)
04/2022
1Liver Transplantation
04/2022
1Activities of Daily Living (ADL)
03/2022
1Cholecystectomy
10/2021
1Length of Stay
03/2021
1Ileostomy
02/2021